banner

CLSA Events, Events

The Reimbursement Decision: Payer and Provider Perspectives

 

Platinum Sponsor

Gilead Projection Logo 2003 one inch
MCRA-logo-sm

Gold Sponsor

Amgen - Copy

Supporter

Biogen

November 17, 2015 | San Francisco, CA

 

Product approval by the FDA is no longer the end of the line for new therapies and technologies. Innovators must prove value to providers and payers in order to generate a reimbursement revenue stream that covers research and development costs and provides adequate profits to fuel the next discovery’s translation and commercialization. To obtain a favorable coverage and payment decision, innovators must meet increasingly complex, demanding and often times opaque evidentiary requirements. During this frank discussion, the decision makers will focus on what outcomes payers and providers expect to see from clinical trials, how they define “value,” how they see mechanisms like bundled payments and accountable care organizations (ACOs) being implemented, and how they measure impact on function and quality of life when they make their decisions.

SPONSOR NOW

Speakers:

Tim Hunter
Vice President, Health Economics, Reimbursement & Public Policy, MCRA.

Tim Maurice
Chief Financial Officer, UC Davis Health System

Alan Rosenberg, M.D.
Vice President, Medical and Clinical Pharmacy Policy, Anthem, Inc.

Brian Solow, M.D., F.A.A.F.P.
Chief Medical Officer, Optum Life Sciences

What:

The Reimbursement Decision: Payer and Provider Perspectives

When:

November 17, 2015

12:00 — 12:45 pm: Check-in & Lunch
12:45 — 1:45 pm: Panel Discussion
1:45 — 2:30 pm: Networking

Where:

Marriott Marquis Hotel
780 Mission St.
San Francisco, CA 94103

Map

Cost:

$100 CLSA Members
$150 Non-Members

Parking:

Parking